Table 1.

Analysis of synergy for the combinations of PPRHs and trastuzumab in SKBR-3 cells.

Dose HpI4 (nM)	Dose HpI6 (nM)	Dose TZ (µg/mL)	CI Media	Description
30	-	100	0.76	Moderate synergism
50	-	100	0.72	Moderate synergism
100	-	100	0.51	Synergism
-	30	100	0.66	Synergism
-	50	100	0.60	Synergism
-	100	100	0.93	Nearly additive

The concentrations of PPRHs and antibodies, the calculated combination index (CI), and the description of the resulting effect are shown.